Journals / Balkan Medical Journal / 2013 / Cilt: 30 - Sayı: 1

Evaluation of the effects of novel nafimidone derivatives on thermal hypoalgesia in mice with diabetic neuropathy

Pages
94–98
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Nafimidone derivatives may be effective in the cases where epilepsy and diabetes occur together since it has shown efficacy against loss of sensation which evolves in diabetic neuropathy over time as well as its antiepileptic effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Diabetic neuropathy (DN) is a common complication in Diabetes Mellitus.
📊
Key Findings & Data:The streptozotocin-induced diabetic rodent is the most commonly used animal model of diabetes and increased sodium channel expression and activity were revealed in this model.
💡
Conclusion & Impact:Conclusion: Nafimidone derivatives may be effective in the cases where epilepsy and diabetes occur together since it has shown efficacy against loss of sensation which evolves in diabetic neuropathy over time as well as its antiepileptic effect.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Diabetic neuropathy (DN) is a common complication in Diabetes Mellitus. The streptozotocin-induced diabetic rodent is the most commonly used animal model of diabetes and increased sodium channel expression and activity were revealed in this model. At this study, we evaluated the effect of three different nafimidone derivatives which have possible anticonvulsant activity on disorders of thermal pain sensation in diabetic mice. Study Design: Randomized animal experiment. Material and Methods: Mice were divided randomly into five groups (5 mice per group): Control, Diabetes, Dibetes+C1, Diabetes+C2, Diabetes+C3. We used hot and cold plate, and tail-immersion tests for assessment of thermal nociceptive responses. Results: Compared with the control group, the hot-plate response time and the number of paw liftings on cold plate as important indicators of loss of sensation increased, but no significant difference (p>0.05) was found in tail-immersion response time test in diabetes group. C3 compound moved it back to control group levels in the all of three tests. C1 and C2 compounds were effective only in cold-plate test. Conclusion: Nafimidone derivatives may be effective in the cases where epilepsy and diabetes occur together since it has shown efficacy against loss of sensation which evolves in diabetic neuropathy over time as well as its antiepileptic effect.

🔖

Cite This Article

ALAGÖZ, A., KARAKURT, A., BATCIOĞLU, K., SATILMIŞ, B., KAMIŞLI, S., GENÇ, M. F., UYUMLU, A. B. (2022). Evaluation of the effects of novel nafimidone derivatives on thermal hypoalgesia in mice with diabetic neuropathy. Balkan Medical Journal, Cilt: 30 - Sayı: 1, 94–98. https://ajindex.com/articles/461592

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Pacio- rek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980:systematic analysis of health examination surveys and epidemiological stud- ies with 370 country-years and 2.7 million participants. Lancet 2011
  2. [CrossRef] 2. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004
  3. [CrossRef] 3. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002
  4. [CrossRef] 4. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008
  5. [CrossRef] 5. Tomlinson DR. Mitogen-actiavated protein kinases as glu- cose transducers for diabetic complications. Diabetologia 1999
  6. [CrossRef] 6. Chan L, Terashima T, Urabe H, Lin F, Kojima H. Pathogene- sis of diabetic neuropathy:bad to the bone. Ann NY Acad Sci 2011
  7. [CrossRef] 7. Konrad R, Mikolaenko I, Tolar J, Liu K, Kudlow J. The potential mechanism of the diabetogenic action of streptozotocin:Inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-b-D-glucos- aminidase. Biochem J 2001
  8. [CrossRef] 8. Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S. Relative importance of transport and alkylation for pancreatic b-cell toxic- ity of streptozotocin. Diabetologia 2000
  9. [CrossRef] 9. Otto KJ, Wyse BD, Cabot PJ, Smith MT. Insulin implants prevent the temporal development of mechanical allodynia and opioid hyposensitivity for 24-wks in streptozotocin (stz)-diabetic wistar rats. Pain Med 2011
  10. [CrossRef] 10. Obrosova IG. Diabetic painful and insensate neuropathy:pathogenesis and potential treatments. Neurothera- peutics 2009
  11. [CrossRef] 11. Hong S, Wiley JW. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Bio Chem 2004
  12. 29341-50. 12. Catterall WA. Structural biology:A 3D view of sodium channels. Nature 2001
  13. [CrossRef] 13. Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeu- tics 2009
  14. [CrossRef] 14. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol